

Seung Woon Paik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5624438/publications.pdf>

Version: 2024-02-01

123
papers

3,856
citations

147801

31
h-index

149698

56
g-index

128
all docs

128
docs citations

128
times ranked

5530
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	3.7	567
2	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	12.1	149
3	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	7.3	144
4	Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. <i>Journal of Hepatology</i> , 2019, 70, 684-691.	3.7	136
5	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. <i>Gut</i> , 2017, 66, 323-329.	12.1	125
6	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. <i>Journal of Hepatology</i> , 2017, 67, 1274-1280.	3.7	120
7	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	7.3	106
8	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.4	104
9	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. <i>Gastroenterology</i> , 2016, 151, 481-488.e1.	1.3	95
10	Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 279.	8.9	70
11	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. <i>Scientific Reports</i> , 2018, 8, 4718.	3.3	68
12	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	8.2	68
13	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	7.3	66
14	Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 833-839.	2.8	66
15	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	3.9	65
16	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
17	Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63.	2.9	64
18	The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 795-801.	3.9	51

#	ARTICLE	IF	CITATIONS
19	The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems: does following these always improve survival rates for <scp>HCC</scp> patients?. Liver International, 2016, 36, 1490-1497.	3.9	51
20	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. Journal of Hepatology, 2015, 62, 1112-1121.	3.7	50
21	Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 1144-1152.	3.7	49
22	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. PLoS ONE, 2014, 9, e112184.	2.5	49
23	Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. European Journal of Endocrinology, 2019, 181, 185-192.	3.7	46
24	Liver Function Assessment Using Albuminâ€“Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Digestive Diseases and Sciences, 2017, 62, 3235-3242.	2.3	44
25	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. PLoS ONE, 2015, 10, e0124434.	2.5	43
26	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 250-258.	8.9	42
27	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clinical and Molecular Hepatology, 2020, 26, 516-528.	8.9	42
28	Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia. Digestive Diseases and Sciences, 2000, 45, 1680-1684.	2.3	38
29	Economic evaluation of the societal costs of hepatitis B in South Korea. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 301-308.	2.8	37
30	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Medicine, 2019, 8, 6986-6994.	2.8	37
31	Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1064-1070.	2.8	35
32	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigenâ€“Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Journal of Infectious Diseases, 2017, 216, 1407-1414.	4.0	33
33	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer, 2021, 10, 52-62.	7.7	30
34	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis, 2014, 234, 270-275.	0.8	29
35	A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Digestive and Liver Disease, 2014, 46, 813-817.	0.9	28
36	Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiation Oncology Journal, 2014, 32, 14.	1.5	28

#	ARTICLE	IF	CITATIONS
37	Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma. American Journal of Surgery, 2015, 209, 391-397.	1.8	27
38	Treatment of Small Hepatocellular Carcinoma (≤2cm) in the Caudate Lobe with Sequential Transcatheter Arterial Chemoembolization and Radiofrequency Ablation. CardioVascular and Interventional Radiology, 2016, 39, 1015-1022.	2.0	27
39	Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. Journal of Viral Hepatitis, 2020, 27, 896-903.	2.0	26
40	Inducible Nitric Oxide Synthase (iNOS) Immunoreactivity and Its Relationship to Cell Proliferation, Apoptosis, Angiogenesis, Clinicopathologic Characteristics, and Patient Survival in Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2001, 29, 133-140.	0.4	25
41	Protein Induced by Vitamin K Antagonistâ€”(PIVKAâ€”) Is a Reliable Prognostic Factor in Small Hepatocellular Carcinoma. World Journal of Surgery, 2013, 37, 1371-1378.	1.6	24
42	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.	1.8	24
43	The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 814-821.	0.8	23
44	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1100-1106.	2.8	23
45	Novel Albuminâ€”Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.	2.3	23
46	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 477-486.	8.9	23
47	Single hepatocellular carcinoma ≤ 3 cm in left lateral segment: Liver resection or radiofrequency ablation. World Journal of Gastroenterology, 2014, 20, 4059.	3.3	22
48	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.	2.9	22
49	Efficacy of pegâ€”interferonâ€”2a plus ribavirin for patients aged 60â€”years and older with chronic hepatitis C in Korea. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 469-476.	2.8	21
50	Inducible Nitric Oxide Synthase Expression in Gastroduodenal Diseases Infected with Helicobacter pylori. Helicobacter, 2001, 6, 37-43.	3.5	20
51	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Annals of Surgical Treatment and Research, 2020, 99, 238.	1.0	20
52	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean Journal of Internal Medicine, 2015, 30, 32.	1.7	19
53	Prognostic significance of miR-122 expression after curative resection in patients with hepatocellular carcinoma. Scientific Reports, 2019, 9, 14738.	3.3	18
54	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology International, 2016, 10, 947-955.	4.2	17

#	ARTICLE	IF	CITATIONS
55	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean Journal of Internal Medicine, 2017, 32, 636-646.	1.7	17
56	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2028-2035.	2.8	17
57	Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiation Oncology Journal, 2018, 36, 25-34.	1.5	16
58	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut and Liver, 2016, 10, 939-947.	2.9	15
59	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World Journal of Gastroenterology, 2016, 22, 3785.	3.3	15
60	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1998-2005.	2.8	15
61	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatology International, 2021, 15, 892-900.	4.2	15
62	Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors. Gut and Liver, 2014, 8, 543-551.	2.9	15
63	Treatment of Naïve HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection Versus TACE Followed by Radiotherapy. Anticancer Research, 2018, 38, 4919-4925.	1.1	14
64	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. International Journal of Epidemiology, 2020, 49, 1562-1571.	1.9	14
65	Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma. Cancers, 2020, 12, 1300.	3.7	14
66	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, e529-e534.	1.6	14
67	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. Digestive and Liver Disease, 2021, 53, 1004-1010.	0.9	14
68	Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. PLoS ONE, 2017, 12, e0179480.	2.5	14
69	Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter?. Cancer Research and Treatment, 2016, 48, 574-582.	3.0	14
70	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut and Liver, 2016, 10, 295.	2.9	14
71	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver, 2016, 10, 796-802.	2.9	14
72	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 3354-3362.	2.3	13

#	ARTICLE	IF	CITATIONS
73	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	2.0	13
74	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	8.9	13
75	Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2015, 33, 276.	1.5	13
76	Changes in Arteriportal Shunts in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Who Were Treated with Chemoembolization Followed by Radiotherapy. <i>Cancer Research and Treatment</i> , 2015, 47, 251-258.	3.0	13
77	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	3.3	13
78	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 283.	8.9	12
79	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	2.5	12
80	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>PLoS ONE</i> , 2019, 14, e0213547.	2.5	12
81	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. <i>Oncotarget</i> , 2017, 8, 52651-52664.	1.8	12
82	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. <i>Hepatology International</i> , 2013, 7, 1010-1018.	4.2	11
83	Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area. <i>Scientific Reports</i> , 2017, 7, 12258.	3.3	11
84	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. <i>BMC Cancer</i> , 2019, 19, 286.	2.6	11
85	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 331-339.	8.9	11
86	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 65-78.	1.7	11
87	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4565-4573.	2.3	11
88	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	7.3	10
89	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	2.5	9
90	Can the model for end-stage liver disease score replace the indocyanine green clearance test in the selection of right hemihepatectomy in Child-Pugh class A?. <i>Annals of Surgical Treatment and Research</i> , 2014, 86, 122.	1.0	8

#	ARTICLE	IF	CITATIONS
91	A randomized, controlled study of peginterferon lambda-1a/ribavirin±daclatasvir for hepatitis C virus genotype 2 or 3. SpringerPlus, 2016, 5, 1365.	1.2	8
92	Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. Annals of Surgical Treatment and Research, 2018, 94, 183.	1.0	8
93	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. Journal of Viral Hepatitis, 2020, 27, 739-746.	2.0	8
94	Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 957-963.	2.8	7
95	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clinical and Molecular Hepatology, 2015, 21, 232.	8.9	7
96	An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. Clinical and Molecular Hepatology, 2019, 25, 400-407.	8.9	7
97	Enhanced Resolution of Eosinophilic Liver Abscess Associated with Toxocariasis by Albendazole Treatment. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 222.	0.4	6
98	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. International Journal of Hyperthermia, 2016, 32, 331-338.	2.5	6
99	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.	2.2	6
100	Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine resistance. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1454-1460.	2.8	5
101	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.	1.5	5
102	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Digestive Diseases and Sciences, 2021, 66, 2816-2825.	2.3	5
103	Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients: Functional cure unlikely. Journal of Viral Hepatitis, 2020, 27, 951-954.	2.0	5
104	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS ONE, 2015, 10, e0144777.	2.5	5
105	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. Korean Journal of Internal Medicine, 2022, 37, 1082-1087.	1.7	5
106	Defining Virologic Relapse in Chronic Hepatitis B. Digestive Diseases and Sciences, 2011, 56, 2432-2438.	2.3	4
107	A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. Hepatology International, 2013, 7, 106-110.	4.2	4
108	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. Journal of Korean Medical Science, 2014, 29, 1113.	2.5	4

#	ARTICLE	IF	CITATIONS
109	Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 168.	8.9	4
110	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 393.	8.9	4
111	Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e410-e416.	3.6	3
112	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. <i>Gut and Liver</i> , 2021, 15, 895-903.	2.9	3
113	Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2020, 14, 368-376.	2.9	3
114	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	1.5	3
115	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	2.5	2
116	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.9	2
117	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.1	2
118	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	2.3	1
119	The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. <i>Journal of Korean Medical Science</i> , 2016, 31, 825.	2.5	1
120	Change of Intrapulmonary Shunt after Liver Transplantation in Irreversible Acute or Chronic Liver Diseases. <i>Sunhwan'gi</i> , 2003, 33, 212.	0.3	0
121	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.6	0
122	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	1.5	0
123	IDDF2020-ABS-0058â€¦48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF). , 2020, , .		0